BioSpace News Archive

SK Life Science, Inc. will present data from ten abstracts, including analyses on drug load and the rate of SUDEP in adults with partial-onset (focal) seizures taking XCOPRI® (cenobamate tablets) CV at the American Epilepsy Society (AES) Annual Meeting, to be held in-person in Nashville, TN, December 2–6, 2022.

RedHill Biopharma Ltd. today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $8.0 million.

EIP Pharma Inc. today announced that a presentation at the 15th Annual Clinical Trials in Alzheimer’s disease (CTAD) meeting in San Francisco demonstrates that neflamapimod may reverse pathologic disease progression in the basal forebrain cholinergic system in the early stages of Alzheimer’s disease.

Scientists at Klick Applied Sciences have discovered a way to transform a continuous glucose monitor (CGM) into a powerful diabetes screening and prevention tool using artificial intelligence.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations related to the ongoing clinical development of STK-001, the first potential new medicine to treat the underlying cause of Dravet syndrome.

Novavax, Inc. today announced that it will participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference.

Company to host webcast conference call on Tuesday, December 6 at 8:00 am ET.

Ovid Therapeutics Inc. (NASDAQ: OVID) today announced that preclinical data supporting its OV329 and OV350 programs in epilepsy and treatment-resistant seizures will be presented at the 2022 American Epilepsy Society (AES) Annual Meeting, taking place December 2-6 in Nashville, Tennessee.

Neurelis, Inc., announced the company will present nine posters at the 76th American Epilepsy Society Annual Meeting (AES), December 2 – 6, 2022, Nashville, TN.

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK.